Dr Baz on the Incidence of AEs With Ide-Cel in Triple-Class&

Dr Baz on the Incidence of AEs With Ide-Cel in Triple-Class–Exposed Multiple Myeloma

Rachid Baz, MD, discusses findings from an analysis of cytopenias and infections in patients with multiple myeloma enrolled in the KarMMa-3 trial.

Related Keywords

Rachid Baz , Department Of Malignant Hematology , Pentecost Family Myeloma Research Center , Moffitt Cancer Center , Malignant Hematology , D , Patients With Multiple Myeloma , Karmma 3 Trial ,